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DC COVID-19 STATS THROUGH MAY 30

(from https://coronavirus.dc.gov/page/coronavirus-data)
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(from https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/)
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The Virginia Hospital & Healthcare Association has launched an online dashboard of currently hospitalized patients with
COVID-19, available beds, and other resources.
The Maryland Emergency Management Agency also maintains a COVID-19 dashboard based on data released by the
Governor’s office and the Maryland Department of Health.

Highlights This Week
 Epidemiological studies have documented very high rate of confirmed Covid19 infection in persons without symptoms raising this as an important vector for
secondary transmission and for prevention strategies. Mask-wearing is an
increasingly important public health tool.
 Significant mental health needs related to Covid-19 are being documented
among the population at large and particularly among those with Covid-19
disease and the health care workforce.
 A high rate of Covid-19 disease presentation and involvement of multiple organ
systems (singly and together) is documented: cardiac, hematologic, GI, ocular,
renal, skin, CNS.
 SARS CoV-2 viral dynamic studies continue to demonstrate lengthy periods of
positive viral RNA tests in the convalescent period.
 The Covid-19 disease hypercoaguable state continues to be documented.
Treatment and prevention approaches are not yet clear. This a major concern many studies are underway.
 Documentation of the stark racial disparities of severe Covid-19 disease and
mortality in the US continues with growing recognition that this is caused by
social determinants of health.
 There is a growing recognition that primary care research is needed to develop
post-Covid-19 disease treatment knowledge. Improved prevention strategies are
needed to minimize risk of severe disease outcomes related to underlying
pulmonary, cardiac and metabolic diseases such as diabetes and obesity all of
which are now well documented as risk factors for severe Covid-19 disease
outcomes.
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BEHAVIORAL HEALTH
Title: Anxiety, Depression, Traumatic Stress, and COVID-19 Related Anxiety in the
UK General Population During the COVID-19 Pandemic
Publisher: pre-pub/not peer reviewed
Publication Date: April 14, 2020
URL: https://www.qualtrics.com/blog/confronting-mental-health/
Key Takeaway: 2000 UK residents reported increased levels of anxiety, depression and
trauma, but not dramatically increased. Risk factors included youth, presence of children at
home, and high estimated personal risk. Low and loss of income predicted anxiety and
depression symptoms, along with pre-existing health conditions and being elderly.
Title: Mental Health Outcomes Among Frontline and Second-Line Health Care
Workers During the Coronavirus Disease 2019 (COVID-19) Pandemic in Italy
Publisher: JAMA Psychiatry
Publication Date: May 28, 2020
URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766378
Key Takeaway: This cross-sectional study of 1379 HCW’s in Italy shows is the first report
on mental health outcomes and associated risk factors among HCWs in Italy during the
COVID-19 pandemic. These results are in line with previous reports from China, confirming
a substantial proportion of mental health issues, particularly among young women and
frontline HCWs. The authors recommend these findings required further monitoring and
specific interventions for HCWs throughout the COVID-19 pandemic to prevent longterm mental health–related disabilities.

CLINICAL KNOWLEDGE
● Diagnostics
Title: Extra-respiratory manifestations of COVID-19
Publisher: International Journal of Antimicrobial Agents
Publication Date: May 25, 2020
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243791/pdf/main.pdf
Key Takeaway: SARS-CoV-2 infection often involves other organs/systems beyond the
respiratory system:
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Title: Viral Load Dynamics in Patients Infected with SARS-CoV-2
Publisher: NEJM Journal Watch (summarizing articles in BMJ and Eur J Clin Micro
Infect Dis)
Publication Date: May 27, 2020
URL: https://www.jwatch.org/na51648/2020/05/27/viral-load-dynamics-patients-infectedwith-sars-cov-2
Key Takeaway: This is a report of two recent publications on viral load dynamics in patients
recovering from Covid-19 infection. Conclusions:
1. Patients with severe COVID-19 shed virus longer and in higher copy numbers.
2. Viral shedding appears to last longer in patients with severe disease, in those with
corticosteroid treatment, in older individuals, and in men.
3. Quantitative RT-PCR and viral infectivity seem to be closely linked.
This information is of value when considering discontinuation of isolation in patients
recovering from COVID-19. Unfortunately, the authors did not investigate the association
between infectivity and time from symptom onset. Such data are urgently awaited.
Title: What Tests Should No Longer Be Distributed for COVID-19 Serology?
Publisher: FDA
Publication Date: May 22, 2020
URL: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqstesting-sars-cov-2#nolonger
Key Takeaway: For our laboratory, research and procurement staff, this is an FDAdistributed list of commercial manufacturers of Covid-19 serological tests that no longer
should be used. Note: FDA had granted Emergency Use Authorization for distribution and
use of Covid-19 serologic tests to a very large number of manufacturers. FDA has now
removed many in an attempt to improve quality standards of Covid-19 serologic testing.
Title: COVID-19 and Liver Dysfunction: a systematic review and meta analysis of
retrospective studies
Publisher: Journal of Medical Virology
Publication Date: May 23, 2020
URL: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26055
Key Takeaway: Meta‐analysis of 20 retrospective studies (3428 patients), identified that
patients with a severe manifestation of COVID‐19 exhibited significantly higher levels of
alanine aminotransferase, aspartate aminotransferase, and bilirubin values with prolonged
prothrombin time. Furthermore, lower albumin level was associated with a severe
presentation of COVID‐19. Liver dysfunction was associated with a severe outcome of
COVID-19 disease. Close monitoring of the occurrence of liver dysfunction is beneficial
in early warning of unfavorable outcomes.

● Critical Care
Title: COVID-19 Infection: Implications for Perioperative and Critical Care Physicians
Publisher: Anesthesiology/ASA Publications
Publication Date: June 2020
URL: https://anesthesiology.pubs.asahq.org/article.aspx?articleid=2763458
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Key Takeaway: This review provides a comprehensive summary of the evidence currently
available to guide management of critically ill patients with COVID-19.Authors review
COVID-19 pathogenesis, presentation, diagnosis, and potential therapeutics, with a focus on
management of COVID-19–associated respiratory failure. The authors draw on literature
from other viral epidemics, treatment of acute respiratory distress syndrome, and recent
publications on COVID-19, as well as guidelines from major health organizations.
Title: Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the
Hypercoagulable State of Severe Coronavirus Disease 2019
Publisher: Critical Care Medicine
Publication Date: May 27, 2020
URL:
https://journals.lww.com/ccmjournal/Abstract/9000/Routine_Venous_Thromboembolism_Pr
ophylaxis_May_Be.95638.aspx
Key Takeaway: This is an observational study of 109 critically ill Covid-19 patients
admitted to the ICU to determine the frequency of venous thromboembolism and the degree
of inflammatory and coagulation marker elevation associated with venous thromboembolism.
VTE was diagnosed in 31 patients (28%) 8 ± 7 days after hospital admission. Twelve patients
(11%) had thromboelastography performed and 58% of these patients had a hypercoagulable
study. The calculated coagulation index was hypercoagulable in 50% of patients with
thromboelastography. This study confirms that Covid-19 results in a hypercoagulable
state and that routine chemical venous thromboembolism prophylaxis may be
inadequate in preventing venous thromboembolism in severe Covid-19.
Title: Management of Venous Thromboembolism During the COVID-19 Pandemic
Publisher: Journal of Vascular Surgery: Venous and Lymphatic Disorders
Publication Date: May 23, 2020
URL: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213333X20303073
Key Takeaway: The authors propose detailed management algorithms treatment and
prevention of venous thromboembolism for patients with and without Covid-19 infection.
Title: Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019
Publisher: Critical Care Medicine
Publication Date: March 29, 2020
URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766543
Key Takeaway: This study from French critical care physicians prospectively performed a
venous ultrasonogram of the inferior limbs for 34 consecutive patients admitted to their ICU
for Covid-19 disease and found deep vein thrombosis in 22 patients (65%) at admission and
in 27 patients (79%) when the venous ultrasonograms performed 48 hours after ICU
admission with 26% proximal, 68% distal and 53% bilateral. In view of the high rate (ie,
79%) of deep vein thrombosis reported in this study, prognosis might be improved with
early detection and a prompt start of anticoagulant therapy. Despite anticoagulant
prophylaxis, 15% of patients in this study developed deep vein thrombosis only 2 days after
ICU admission.
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Title: Pulmonary and cardiac pathology in African American patients with COVID-19:
an autopsy series from New Orleans
Publisher: The Lancet
Publication Date: May 27, 2020
URL: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30243-5/fulltext
Key Takeaway: This is a report on the cardiopulmonary findings of the first autopsy series
of ten African Americans with recorded cause of death of COVID-19. The distinctive
pathological findings are likely to have important implications for treatment of severe disease
in this patient population. The authors state, “We believe that effective therapy for this
patient demographic—and probably patients with severe infection across demographics—
should target not only the viral pathogen, but also the thrombotic and microangiopathic
effects of the virus, and possibly a maladaptive immune response to viral infection.”
Title: Angiopoietin-2 as a Marker of Endothelial Activation Is a Good Predictor Factor
for Intensive Care Unit Admission of COVID-19 Patients
Publisher: Angiogenesis
Publication Date: May 27, 2020
URL: https://link.springer.com/article/10.1007/s10456-020-09730-0
Key Takeaway: The authors propose angiopoietin-2 is a relevant predictive factor for ICU
direct admission in COVID-19 patients. This is a prospective cohort study that enrolled 40
consecutive COVID-19 patients admitted to the emergency department that fulfilled criteria
for hospitalization; 20 were admitted in conventional wards without any ICU transfer during
hospitalization and 20 others were directly transferred to ICU. Angiopoietin-2 cut-off of
5000 pg/mL was the best predictor for ICU outcome further confirmed in multivariate
analysis after adjustment for creatinine, CRP or D-dimers. This result showing an endothelial
activation reinforces the hypothesis of a COVID-19-associated microvascular dysfunction.

● Emergency Medicine
Title: Conscious Proning: An Introduction of a Proning Protocol for Non-Intubated,
Awake, Hypoxic Emergency Department COVID-19 Patients
Publisher: Academic Emergency Medicine
Publication Date: May 27, 2020
URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.14035
Key Takeaway: Proning may prove to be of great clinical benefit to the large number of
COVID-19 patients with severe hypoxemia. This article provides appropriate inclusion and
exclusion criteria for safe and effective use of prone positioning of awake COVID-19
patients in the ED, as a non-invasive treatment that may prevent worsening hypoxemia and
respiratory failure.

● Primary Care
Title: Lifestyle Risk Factors, Inflammatory Mechanisms, and COVID-19
Hospitalization: A Community-Based Cohort Study of 387,109 Adults in UK
Publisher: Brain, Behavior and Immunity
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Publication Date: May 23, 2020
URL: https://doi.org/10.1016/j.bbi.2020.05.059
Key Takeaway: This is the first large-scale general population study on lifestyle risk factors
(smoking, physical inactivity, obesity, and excessive alcohol intake) for COVID-19 using
prospective cohort data with national registry linkage to hospitalisation. Participants were
387,109 men and women (56.4 ± 8.8 yr; 55.1% women) residing in England from UK
Biobank study. Finding were:
● Poorer lifestyle habits and elevated C-reactive protein was associated with greater
risk of COVID-19 hospitalisation.
● Unhealthy lifestyle behaviours in combination accounted for up to 51% of the
population attributable fraction of severe COVID-19.
● Low grade inflammation may be an important mechanism.
The authors recommend, “Adopting simple lifestyle changes could lower the risk of
severe COVID-19 infection.”
Title: Decline in Child Vaccination Coverage During the COVID-19 Pandemic —
Michigan Care Improvement Registry, May 2016–May 2020
Publisher: MMWR/CDC
Publication Date: May 22, 2020
URL: https://www.cdc.gov/mmwr/volumes/69/wr/mm6920e1.htm?s_cid=mm6920e1_w
Key Takeaway: The observed declines in vaccination coverage might leave children and
communities vulnerable to vaccine-preventable diseases such as measles due to a decline
in herd immunity. Concerted efforts are needed to ensure rapid catch-up for children who are
not up-to-date with age-appropriate vaccinations.

Title: It’s time to shift the research focus to studies on living with this disease
Publisher: British Medical Journal
Publication Date: May 22, 2020
URL: https://www.bmj.com/content/369/bmj.m2035
Key Takeaway: With 4.7 million people worldwide and over 300 000 have died and without
a vaccine or disappearance of the virus, we could be living with COVID-19 disease for the
foreseeable future, possibly years. Beyond the hospital, long term outcomes of COVID-19
are unknown. Anecdotal reports have included symptoms that last for weeks or months.
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Sequelae of COVID-19 infection might include worsening of chronic conditions and
profound needs for rehabilitation. There is much to learn about transmission, immunity and
its durability, and, as with other coronaviruses, the potential for reinfection. The authors call
for cohort studies of such patients (see below Epidemiology), “If we are going to be
managing COVID-19 for the next several years…we need to understand and optimize care
before, during, and beyond the hospital.”
●

Therapeutics
Title: Efficacy and safety of convalescent plasma for severe COVID-19 based on
evidence in other severe respiratory viral infections: a systematic review&meta-analysis
Publisher: Canadian Medical Assn Journal
Publication Date: May 22, 2020
URL: https://www.cmaj.ca/content/early/2020/05/22/cmaj.200642.long
Key Takeaway: In this is a meta-analysis of studies on the use of convalescent plasma in
treatment for several severe respiratory infections – mostly influenza – and concludes that in
non-COVID-19 severe respiratory viral infections there is indirect, very low-quality evidence
that raises the possibility that convalescent plasma has minimal or no benefit in the treatment
of COVID-19 and low-quality evidence that it does not cause serious adverse events. The
authors assert that the merit of convalescent plasma is its apparent low rate of serious
adverse effects and although this may be an advantage over other unproven therapies
for COVID-19, it is insufficient to justify its use without associated evidence of efficacy.
Title: Impact of anticoagulation prior to COVID-19 infection: a propensity scorematched cohort study
Publisher: Blood
Publication Date: May 27, 2020
URL:
https://ashpublications.org/blood/article/doi/10.1182/blood.2020006941/458074/Impact-ofanticoagulation-prior-to-COVID19
Key Takeaway: This report fromNew York is a retrospective analysis of 3,772 patients with
confirmed COVID-19, comparing outcomes among those who were and were not receiving
anticoagulation for unrelated indications at the time of COVID-19 diagnosis. There was no
statistically significant difference in survival (p= 0.367) and time to mechanical
ventilation (p=0.742) between the two groups.
Title: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Publisher: NEJM
Publication Date: May 27, 2020
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2015301?url_ver=Z39.882003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Key Takeaway: This is an open label phase 3 RCT of 397 patients with severe Covid-19
NOT requiring mechanical ventilation with no placebo control to assess the impact of a 5 or
10-day course of remdesivir looking at an endpoint of clinical status assessed on a 7-point
ordinal scale. Results: “In patients with severe Covid-19 not requiring mechanical
ventilation, our trial did not show a significant difference between a 5-day course and a
10-day course of remdesivir.”
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RESOURCES: DECISION-SUPPORT TOOLS, CALCULATORS,
TREATMENT ALGORITHMS
Title: Clinical management of COVID-19
Publisher: WHO
Publication Date: May 27, 2020
URL: https://www.who.int/publications-detail/clinical-management-of-covid-19
Key Takeaway: WHO released their updated (62 page very detailed) Clinical Management
guidelines intended for clinicians caring for COVID-19 patients during all phases of
their disease (i.e. screening to discharge) and includes:
● Updated COVID-19 care pathway, treatment of acute and chronic infections,
management of neurological and mental manifestations, noncommunicable diseases,
rehabilitation, palliative care and ethical principles..
● One of the key changes in the guidance is the recommendation to discontinue
transmission-based precautions (including isolation) and release from the COVID-19
care pathway for symptomatic patients 10 days after symptom onset, plus an
additional three days without symptoms (without fever and respiratory symptoms).
● Recommended prevention of complications include:
o Prevention of venous thromboembolismIn patients (adults and adolescents) when
hospitalized
o WHO recommends that the listed drugs including antivirals, immunomodulators
and other adjunctive therapies should not be administered as treatment or
prophylaxis for COVID-19 outside the context of clinical trials.
o WHO recommends against the routine use of systemic corticosteroids for
treatment of viral pneumonia.
Title: Sickle Cell Disease (SCD) Patients Presenting to the Emergency Department
During the COVID-19 Pandemic: Considerations and a Checklist [librarian]
Publisher: American Society of Hematology
Publication Date: May 18, 2020
URL: https://www.hematology.org/covid-19/sickle-cell-disease-er-checklist
Key Takeaway: This is an ASH expert panel-derived checklist to assist in the evaluation
of SCD patients in the ED presenting with symptoms concerning for COVID-19 and/or
complications of SCD, with SCD-specific considerations for evaluation and treatment.
Preliminary data suggests that SCD patients may have higher mortality from COVID-19
due to underlying predisposing conditions related to SCD (cardiac diastolic dysfunction,
asthma, pulmonary hypertension, cerebrovascular disease, renal dysfunction, thrombotic risk)
and/or severe SCD complications such as acute chest syndrome or PE secondary to COVID19 infection.
Title: Medicine Basecamp
Publisher: McMaster University and University of Toronto
Publication Date: March 30, 2020
URL: https://www.theinternatwork.com/basecamp and
https://onlinelibrary.wiley.com/doi/abs/10.1111/medu.14213
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Key Takeaway: This is an education resource designed for trainees (but would be useful
for any clinicians) who are refreshing their internal medicine content knowledge for
redeployment for Covid-19 clinical care. Designed as a 10 week on-line curriculum, each
subspecialty week consists of five medicine topic podcasts outlining physiology, history,
physical, investigations, and management. A visual aid consolidates material and assists with
information recall. Practical management strategies are also provided.

HEALTH WORKFORCE
Title: How can airborne transmission of COVID-19 indoors be minimised?
Publisher: Environment International
Publication Date: May 27, 2020
URL: https://doi.org/10.1016/j.envint.2020.105832
Key Takeaway: Evidence is strengthening for airborne transmission of the SARS CoV-2
virus in addition to more widely recognized transmission via larger respiratory droplets and
direct contact with infected people or contaminated surfaces. This article outlines the use of
engineering controls in public buildings, including hospitals, shops, offices, schools,
kindergartens, libraries, restaurants, cruise ships, elevators, conference rooms or public
transport, in parallel with effective application of other controls (including isolation and
quarantine, social distancing and hand hygiene), as additional important measure globally to
reduce the likelihood of transmission and thereby protect healthcare workers, patients and the
general public.
Title: Assessment of the Qualitative Fit Test and Quantitative Single-Pass Filtration
Efficiency of Disposable N95 Masks Following Gamma Irradiation
Publisher: JAMA
Publication Date: May 26, 2020
URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766200
Key Takeway: The use of cobalt-60 gamma radiation does work as a sterilization method for
re-use of N95's, but there was significant degradation of the mask, and thus not
recommended.

EPIDEMIOLOGY AND PUBLIC HEALTH
Title: COVID-19: in the footsteps of Ernest Shackleton
Publisher: British Medical Journal: Thorax
Publication Date: May 27, 2020
URL: https://thorax.bmj.com/content/thoraxjnl/early/2020/05/27/thoraxjnl-2020215091.full.pdf
Key Takeaway: This is an epi study of all 217 passengers and crew on board a cruise ship
(on a cruise to Antarctica – thus the reference to Shackleton) found 81% of Covid-19 positive
passengers had no symptoms. Of the 217 passengers, 128 (59%) were positive for COVID19 on RT–PCR. Of the COVID-19-positive patients, 24 (19% ) were symptomatic; and 8
(6.2%) required medical evacuation; 4 (3.1%) were intubated and ventilated; and the
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mortality was 1 (0.8%. The majority of COVID-19-positive patients were asymptomatic
(81%, 104 patients).
Title: Research Letter: Comparison of Clinical Characteristics of Patients with
Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China [clinician]
Publisher: JAMA
Publication Date: May 27, 2020
URL:
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766237?utm_source=For_T
he_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052720
Key Takeaway: This epi study traced close contacts of Covid-19 patients from the Wuhan
Seafood Market and found of the 78 close contacts who tested RT-PCR positive for SARS
CoV-2, 33 (42%) had no symptoms. If confirmed, this very high rate of asymptomatic
infection could represent an important vector for secondary transmission and for prevention
strategies.
Title: Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO
Clinical Characterisation Protocol: prospective observational cohort study
Publisher: BMJ
Publication Date: May 22 2020
URL: https://www.bmj.com/content/369/bmj.m1985
Key Takeaway: Prospective observational cohort study across 208 hospitals reporting on
over 20,000 patients. Overall, the authors concluded in study participants, mortality was
high, independent risk factors were increasing age, male sex, and chronic comorbidity,
including obesity. NB: this ongoing prospective cohort study will likely produce
important findings on the epidemiology, natural history and clinical management of
patients with Covid-19 infection.
Title: Hospitalization and Mortality among Black Patients and White Patients with
Covid-19
Publisher: NEJM
Publication Date: May 27, 2020
URL: https://www.nejm.org/doi/full/10.1056/NEJMsa2011686
Key Takeaway: In a large retrospective cohort study (over 3600 patients) from Louisiana,
76.9% of the patients who were hospitalized with Covid-19 and 70.6% of those who
died were black, whereas blacks comprise only 31% of the Ochsner Health population.
Black race was not associated with higher in-hospital mortality than white race, after
adjustment for differences in sociodemographic and clinical characteristics on admission.
Title: Morbid Obesity as an Independent Risk Factor for COVID-19 Mortality in
Hospitalized Patients Younger than 50
Publisher: Obesity
Publication Date: May 23, 2020
URL: https://onlinelibrary.wiley.com/doi/abs/10.1002/oby.22913
Key Takeaway: Retrospective analysis of 3,406 COVID-19 patients in NYC.
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For the younger population (572 patients), BMI above 40 kg/m2 was independently
associated with mortality. For the older population (1,076 patients), BMI above 40 kg/m2
was also independently associated with mortality to a lesser extent. This study demonstrates
that hospitalized patients younger than 50 with morbid obesity are more likely to die
from COVID-19.
EMERGING CONVERSATIONS*
*This section aims to spread emerging ideas from the professional rumor mill, in an effort to
keep decision makers apprised of topics that are brewing. While this information may become
part of the COVID pedagogy, it currently represents non-scientific, non-evidence-based
propositions. Accordingly, we do not recommend incorporation into clinical guidelines.
Title: Editoria Comment - Face coverings for the public: Laying straw men to rest
Publisher: Journal of Evaluation in Clinical Practice
Publication Date: May 26, 2020
URL: https://doi.org/10.1111/jep.13415
Key Takeaway: This is an evidence based narrative rebuttal of criticisms of the
effectiveness of face coverings/masks in preventing the transmission of the
Coronavirus/COVID-19. Evidence of asymptomatic carriage of Sars‐CoV‐2 is strong
and consistent, the public health rationale for the public use of face masks is to minimize
forward spread of this virus. The author Dr Trisha Greenhalgh is an expert practitioner of
evidence based medicine.
Title: Hydroxychloroquine (HCQ) or chloroquine with or without a macrolide for
treatment of COVID-19: a multinational registry analysis
Publisher: The Lancet
Publication Date: May 22, 2020
URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)311806/fulltext
Key Takeaway: This is a report from a multinational registry that comprised data from
671 hospitals in six continents and 15,000 patients who received HCQ or chloroquine were
about twice as likely to die compared to controls who did not receive these agents after
adjusting for covariates (18.0% for hydroxychloroquine and 16% for chloroquine versus
9.3% for controls). The authors conclude: “We were unable to confirm a benefit of
hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital
outcomes for COVID-19. Each of these drug regimens was associated with decreased inhospital survival and an increased frequency of ventricular arrhythmias when used for
treatment of COVID-19.”
NOTE: A group of more than 140 scientists, researchers, and statisticians have written an
open letter to the Lancet and the authors of this study raising concerns about the integrity
of the results and calling for the release of patient data and for the findings to be validated
by the World Health Organization (WHO), or at least one other independent institution.
Lancet did issue a correction to some specific data reported but that the overall findings
remain unchanged. See: https://www.tctmd.com/news/lancet-covid-19hydroxychloroquine-study-faces-data-integrity-questions
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Title: Remdesivir: An Important First Step (Raphael Dolin, MD & Martin Hirsch
MD)
Publisher: NEJM
Publication Date: May 27, 2020
URL:
https://www.nejm.org/doi/full/10.1056/NEJMe2018715?query=recirc_curatedRelated
_article
Key Takeaway: This is an thoughtful editorial by two researchers experienced in HIV
therapeutic development about what we currently know, don’t know and need to know
about the role of remdesivir looking at the study reported above and the one reported last
week (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home):
● Remdesivir’s effect appears to be modest.
● Timing of initiation of treatment with an antiviral such as remdesivir, as well as the
underlying clinical status of the patient, may have important effects on the outcomes of
therapy and
● Since the pathogenesis of Covid-19 involves not only virus replication, but also
immunomodulation and inflammation, studies of combination therapy with other
antivirals and antiinflammatory agents in appropriate sequence are of high priority (and
plans for such studies are already under way).
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